0.35
+4.55%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Recce Pharmaceuticals
Its shares trade on ASX under the ticker RCE.AX. It has been listed since 15 January 2016. In the fiscal year to 30 June 2025, it reported revenue of A$7.5m and a net loss of A$21.4m. At that date it held total assets of A$12.4m and shareholders' equity of −A$3.1m.
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The Company’s anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are 100% water soluble at all pH levels in their liquid form.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Jan 2016
- Website
- recce.com.au ↗
Leadership
Pay as last reported
- Dr. John PrendergastIndependent Non- Executive Chairman of the BoardA$120,000
- Mr. James GrahamChief Executive Officer, Managing Director, Executive Director, since 2015A$548,202
- Mr. Justin ReynoldsChief Financial Officer
- Ms. Michele DiliziaChief Scientific Officer, Executive Director, since 2015A$368,942
- Dr. Philip SuttonVice President of Translational Sciences
- Dr. Justin WardExecutive Director and Principal Quality Chemist, since 2019A$207,971
- Mr. Daniel AstudilloHead of Marketing
- Mr. Thomas JarrettOperations Manager
- Ms. Maggie NiewidokCompany Secretary
- Mr. Alistair McKeoughNon-Executive Director, since 2017
- Dr. Alan DuntonNon-Executive Independent DirectorA$60,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Recce Pharmaceuticals Ltd. develops anti-infective drugs with multi-layered mechanisms of action.
- RECCE 327 targets serious bacterial infections including superbugs as an IV and topical therapy.
- RECCE 529 addresses viral infections with 100% water solubility across all pH levels.
Weaknesses
- Recce Pharmaceuticals Ltd. has no commercialized products as of 2023.
- The company relies on R&D for anti-infective pipeline development.
- RECCE 435 is an orally administered therapy still in development.
Opportunities
- Recce Pharmaceuticals Ltd. targets the growing anti-infective market in Australia.
- The company's anti-infectives address superbug resistance in the Health Care sector.
- RECCE 327 could expand into global markets for serious infections.
Threats
- Recce Pharmaceuticals Ltd. faces competition from established pharmaceutical companies.
- The anti-infective market is highly regulated by health authorities.
- R&D delays could impact the timeline for RECCE 435 approval.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.